These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25347010)

  • 21. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.
    Samarasinghe S; Clesham K; Iacobelli S; Sbianchi G; Knol C; Hamladji RM; Socié G; Aljurf M; Koh M; Sengeloev H; Dalle JH; Robinson S; Van Lint MT; Halkes CJM; Beelen D; Mufti GJ; Snowden J; Blaise D; de Latour RP; Marsh J; Dufour C; Risitano AM;
    Am J Hematol; 2019 Jan; 94(1):80-86. PubMed ID: 30328134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Blaise D; Lopez-Corral L; Vigouroux S; Craddock C; Attal M; Jindra P; Goker H; Socié G; Chevallier P; Browne P; Sandstedt A; Duarte RF; Nagler A; Mohty M
    Bone Marrow Transplant; 2014 Mar; 49(3):389-96. PubMed ID: 24419525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Excellent overall and chronic graft-versus-host-disease-free event-free survival in Fanconi anaemia patients undergoing matched related- and unrelated-donor bone marrow transplantation using alemtuzumab-Flu-Cy: the UK experience.
    Bernard F; Uppungunduri CRS; Meyer S; Cummins M; Patrick K; James B; Skinner R; Tewari S; Carpenter B; Wynn R; Veys P; Amrolia P;
    Br J Haematol; 2021 May; 193(4):804-813. PubMed ID: 33855694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.
    Medd PG; Peniket AJ; Littlewood TJ; Pearce R; Perry J; Kirkland KE; Shaw BE; Potter MN; Craddock CF; Milligan DW; Fielding AK; Marks DI; Cook G;
    Bone Marrow Transplant; 2013 Jul; 48(7):982-7. PubMed ID: 23318533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion.
    Schmidt-Hieber M; Schwarck S; Stroux A; Ganepola S; Reinke P; Thiel E; Uharek L; Blau IW
    Int J Hematol; 2010 Jun; 91(5):877-85. PubMed ID: 20490728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation.
    Meyer RG; Wagner EM; Konur A; Bender K; Schmitt T; Hemmerling J; Wehler D; Hartwig UF; Roosnek E; Huber C; Kolbe K; Herr W
    Bone Marrow Transplant; 2010 Apr; 45(4):668-74. PubMed ID: 19684624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.
    Morris EC; Rebello P; Thomson KJ; Peggs KS; Kyriakou C; Goldstone AH; Mackinnon S; Hale G
    Blood; 2003 Jul; 102(1):404-6. PubMed ID: 12623851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alemtuzumab for the prevention and treatment of graft-versus-host disease.
    Kanda J; Lopez RD; Rizzieri DA
    Int J Hematol; 2011 May; 93(5):586-593. PubMed ID: 21369856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
    Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.
    Popat U; Carrum G; May R; Lamba R; Krance RA; Heslop HE; Brenner MK
    Bone Marrow Transplant; 2005 Jun; 35(12):1127-32. PubMed ID: 15834432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy.
    Szuszies CJ; Hasenkamp J; Jung W; Koch R; Trümper L; Wulf GG
    Int J Hematol; 2014 Nov; 100(5):425-8. PubMed ID: 25258193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
    Marsh RA; Kim MO; Liu C; Bellman D; Hart L; Grimley M; Kumar A; Jodele S; Myers KC; Chandra S; Leemhuis T; Mehta PA; Bleesing JJ; Davies SM; Jordan MB; Filipovich AH
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1625-31. PubMed ID: 24035782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
    Pérez-Simón JA; Kottaridis PD; Martino R; Craddock C; Caballero D; Chopra R; García-Conde J; Milligan DW; Schey S; Urbano-Ispizua A; Parker A; Leon A; Yong K; Sureda A; Hunter A; Sierra J; Goldstone AH; Linch DC; San Miguel JF; Mackinnon S;
    Blood; 2002 Nov; 100(9):3121-7. PubMed ID: 12384408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
    Gärtner F; Hieke S; Finke J; Bertz H
    Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab.
    von dem Borne PA; Beaumont F; Starrenburg CW; Oudshoorn M; Hale G; Falkenburg JH; Fibbe WE; Willemze R; Barge RM
    Haematologica; 2006 Nov; 91(11):1559-62. PubMed ID: 17082014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease-associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation.
    Nguyen Y; Al-Lehibi A; Gorbe E; Li E; Haagenson M; Wang T; Spellman S; Lee SJ; Davidson NO
    Blood; 2010 Apr; 115(17):3625-31. PubMed ID: 20177049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab in allogeneic hematopoetic stem cell transplantation.
    Poiré X; van Besien K
    Expert Opin Biol Ther; 2011 Aug; 11(8):1099-111. PubMed ID: 21702703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
    Chakraverty R; Peggs K; Chopra R; Milligan DW; Kottaridis PD; Verfuerth S; Geary J; Thuraisundaram D; Branson K; Chakrabarti S; Mahendra P; Craddock C; Parker A; Hunter A; Hale G; Waldmann H; Williams CD; Yong K; Linch DC; Goldstone AH; Mackinnon S
    Blood; 2002 Feb; 99(3):1071-8. PubMed ID: 11807015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.